Business
Collaboration with CTTQ for bepirovirsen
GSK plc has entered an exclusive strategic collaboration with SBP Group, a Chinese hepatology market leader, to accelerate the launch of bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, which is under priority regulatory review in China and affects 75 million people there. This agreement provides scaled access to over 5,000 medical centers in China at launch, with SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., handling importation, distribution, and promotional activities, while GSK retains regulatory and global medical strategy responsibilities. The collaboration also grants GSK the opportunity to review SBP Group's early-stage pipeline for potential future collaborations outside China, and CTTQ will purchase bepirovirsen from GSK under agreed supply terms. Disclaimer*
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 11 May 2026, London, UK\n \nGSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch\n· Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China\n· Chronic hepatitis B affects 75 million people in China and is a national health priority\n· Collaboration provides scaled access to over 5,000 medical centres in China at launch\n· Agreement gives GSK the ability to review SBP Group's early-stage pipeline for potential collaboration opportunities\n \n \n \nGSK plc (LSE/NYSE: GSK) today announced that it has entered into an exclusive strategic collaboration with Sino Biopharmaceutical, (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to accelerate bepirovirsen in mainland China at launch. Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B (CHB) under priority regulatory review in China. CTTQ is a market leader in hepatitis B in China with one of the country's most comprehensive liver disease portfolios and a broad commercial footprint covering more than 5,000 medical centres across care settings. CTTQ has played a significant role in advancing the diagnosis and treatment of hepatitis B in China. \n \nThe collaboration combines GSK innovation with CTTQ's local scale and in-market execution to reach more patients, more quickly. Under the agreement, CTTQ will be responsible for importation, distribution, hospital access, and promotional and non-promotional activities for bepirovirsen in mainland China. GSK will remain the marketing authorisation holder and retain responsibility for regulatory, quality, pharmacovigilance and global medical strategy. The agreement also grants GSK the ability to review certain early-stage pipeline assets of the SBP Group to evaluate the potential for collaboration opportunities outside China.\n \nMike Crichton, President International, GSK, said: \"Chronic hepatitis B affects 75 million people in China1 and is a leading cause of liver cancer in the country.2 By combining GSK's innovation with CTTQ's extensive local scale and execution, we want to reach more patients, deliver greater impact, and directly address on...